JP2013529645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529645A5 JP2013529645A5 JP2013516830A JP2013516830A JP2013529645A5 JP 2013529645 A5 JP2013529645 A5 JP 2013529645A5 JP 2013516830 A JP2013516830 A JP 2013516830A JP 2013516830 A JP2013516830 A JP 2013516830A JP 2013529645 A5 JP2013529645 A5 JP 2013529645A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaralkyl
- amine
- aralkyl
- heteroaryl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heteroaryloxyl Chemical group 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 150000001412 amines Chemical class 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000005035 acylthio group Chemical group 0.000 claims description 12
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 12
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims description 12
- 125000005108 alkenylthio group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 150000003973 alkyl amines Chemical class 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 12
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims description 12
- 125000005109 alkynylthio group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 12
- 150000003974 aralkylamines Chemical class 0.000 claims description 12
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 12
- 150000004982 aromatic amines Chemical class 0.000 claims description 12
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 12
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 12
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- 125000005110 aryl thio group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 12
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 12
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 12
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 10
- 150000003077 polyols Chemical class 0.000 claims description 10
- 229920006295 polythiol Polymers 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000006636 nicotinic acid Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 12
- 210000002966 serum Anatomy 0.000 claims 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 9
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 6
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 4
- 108010082126 Alanine transaminase Proteins 0.000 claims 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 239000011664 nicotinic acid Substances 0.000 claims 4
- 229960003512 nicotinic acid Drugs 0.000 claims 4
- 235000001968 nicotinic acid Nutrition 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 108010028554 LDL Cholesterol Proteins 0.000 claims 3
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 3
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007270 Carcinoid syndrome Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000002141 Pellagra Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 2
- 206010047139 Vasoconstriction Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 102000000072 beta-Arrestins Human genes 0.000 claims 2
- 108010080367 beta-Arrestins Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- 229940116269 uric acid Drugs 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 206010019837 Hepatocellular injury Diseases 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 208000005736 Nervous System Malformations Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 231100000437 hepatocellular injury Toxicity 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(*)(c1c(*)c(*)c(*)c(*)n1)N1CCCC*CCCCC1 Chemical compound *C(*)(c1c(*)c(*)c(*)c(*)n1)N1CCCC*CCCCC1 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35824510P | 2010-06-24 | 2010-06-24 | |
| US61/358,245 | 2010-06-24 | ||
| PCT/US2011/041869 WO2011163612A1 (en) | 2010-06-24 | 2011-06-24 | Niacin mimetics, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529645A JP2013529645A (ja) | 2013-07-22 |
| JP2013529645A5 true JP2013529645A5 (https=) | 2014-08-07 |
| JP5925770B2 JP5925770B2 (ja) | 2016-05-25 |
Family
ID=45371840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516830A Expired - Fee Related JP5925770B2 (ja) | 2010-06-24 | 2011-06-24 | ナイアシン模倣体、およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8937063B2 (https=) |
| EP (1) | EP2584899B1 (https=) |
| JP (1) | JP5925770B2 (https=) |
| AU (1) | AU2011270719B2 (https=) |
| CA (1) | CA2802945A1 (https=) |
| WO (1) | WO2011163612A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5925771B2 (ja) * | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| AU2016348638A1 (en) * | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US11633554B1 (en) * | 2019-06-11 | 2023-04-25 | Luca Puviani | Adaptive systems and methods for delivery of a medicament |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4021436A (en) | 1974-03-15 | 1977-05-03 | Claudio Cavazza | Derivatives of nicotinic acid with amines variously substituted |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4503223A (en) | 1983-08-11 | 1985-03-05 | Usv Pharmaceutical Corporation | Process for the purification of N-morpholinoalkyl dihydropyridines |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP0643965B1 (en) | 1993-09-20 | 2013-05-08 | Abbott Laboratories | Nicotinic acid compositions for treating hyperlipidemia |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US6603000B2 (en) * | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| EP1636187A1 (en) * | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
| CN101076331A (zh) * | 2004-11-05 | 2007-11-21 | 艾尼纳制药公司 | 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物 |
| US20070105793A1 (en) * | 2005-11-04 | 2007-05-10 | Curt Hendrix | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease |
| KR101403887B1 (ko) | 2006-08-03 | 2014-06-20 | 트러스티즈 오브 터프츠 칼리지 | 홍조화를 유발하지 않는 니아신 유사체, 및 이의 사용 방법 |
| MX2009009126A (es) * | 2007-03-01 | 2009-10-28 | Concourse Health Sciences Llc | Isomeros de niacinato de inositol y usos de los mismos. |
| WO2010056549A1 (en) * | 2008-10-29 | 2010-05-20 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| US8551016B2 (en) * | 2008-12-01 | 2013-10-08 | Oasis Diagnostics Corp. | Multi compartment body part scraping fluid collection device |
| JP5925771B2 (ja) * | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
-
2011
- 2011-06-24 WO PCT/US2011/041869 patent/WO2011163612A1/en not_active Ceased
- 2011-06-24 AU AU2011270719A patent/AU2011270719B2/en not_active Ceased
- 2011-06-24 JP JP2013516830A patent/JP5925770B2/ja not_active Expired - Fee Related
- 2011-06-24 EP EP11799002.8A patent/EP2584899B1/en not_active Not-in-force
- 2011-06-24 CA CA2802945A patent/CA2802945A1/en not_active Abandoned
- 2011-06-24 US US13/168,629 patent/US8937063B2/en not_active Expired - Fee Related
-
2014
- 2014-12-10 US US14/566,343 patent/US20150094303A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529645A5 (https=) | ||
| CN103096895B (zh) | 烟酸模拟物及其使用的方法 | |
| AU2011270719B2 (en) | Niacin mimetics, and methods of use thereof | |
| CN110025608A (zh) | 降低心血管疾病风险的方法 | |
| JP2014193913A (ja) | 安定化されたカリスバメートの小児用懸濁液 | |
| JP2018537513A5 (https=) | ||
| JP2020516622A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| AU2004212824A1 (en) | Medicament comprising noble metal fine particles | |
| TW200812592A (en) | Use of strobilurins for the treatment of disorders of iron metabolism | |
| JP6761347B2 (ja) | 脂質異常症治療剤 | |
| JP2017095428A (ja) | 脂質代謝改善剤 | |
| JP7418502B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| JPWO2015030033A1 (ja) | 脂質異常症治療剤 | |
| CN104869988B (zh) | 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在治疗动脉粥样硬化中的用途 | |
| WO2021107060A1 (ja) | ピルフェニドンの副作用を軽減するための医薬 | |
| WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
| CN108546268A (zh) | 用于治疗动脉粥样硬化的化合物及其应用 | |
| AU2015203711A1 (en) | Niacin mimetics, and methods of use thereof | |
| WO2018092765A1 (ja) | 経鼻投与用医薬組成物 | |
| HK1221467B (zh) | 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其新的医药用途 | |
| AU2013209770A1 (en) | Deuterated alpha-lipoic acid | |
| CN105669531A (zh) | 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其新的医药用途 |